Meeting highlights PRAC 2326 October 2023 GLP-1 receptor agonists: available evidence not supporting link with thyroid cancer
Your GP or prescriber will assess your complete medical history, current medications, and individual risk factors before confirming that this combination is suitable for you
Pausing and restarting can affect appetite regulation and gastric motility patterns, potentially causing temporary gastrointestinal upset or weight fluctuations
You may be a good candidate for GLP-1 treatment if you: Have been diagnosed with type 2 diabetes Have obesity, or a body mass index (BMI) of 30 or higher Have overweight (a BMI of 25 to 29.9) plus at least one weight-related condition, such as heart disease or type 2 diabetes Ultimately, the decision to start treatment for weight loss is up to you and your healthcare provider
This comprehensive support helps keep your weight loss journey on track and aligned with your health goals
Yet, surprisingly, no injectable formulation of serratiopeptidase is marketed